Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 2/2009

01.02.2009 | Review Article

Economics of Treatments for Non-Small Cell Lung Cancer

verfasst von: Prof. Christos Chouaid, Kukovi Atsou, Gilles Hejblum, Alain Vergnenegre

Erschienen in: PharmacoEconomics | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness of treatments for the different stages of NSCLC, with particular emphasis on more recently approved agents.
Numerous economic analyses in NSCLC have been conducted, with a variety of methods and in a number of countries. In patients with localized disease, adjuvant chemotherapy appears to have greater cost effectiveness than observation; however, there are few published data. In locally advanced disease, combined modalities (chemotherapy, surgery and/or radiotherapy) are probably cost effective, but high-quality economic analyses are lacking. In advanced NSCLC, third-generation chemotherapies used in the first-line setting can be administered with acceptable incremental cost effectiveness. In the second-line setting, new agents (docetaxel, pemetrexed and erlotinib) have acceptable cost effectiveness. The lack of cost-utility analyses for elderly patients and patients with a poor prognosis rules out firm conclusions.
This review suggests that most therapies for NSCLC are cost effective when the patient has a good performance status, with an incremental costeffectiveness ratio under $US50 000 per life-year gained in the majority of cases.
Literatur
1.
Bordeleau L. Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 2006; 5: 129–41PubMedCrossRef
2.
Dooms CA, Lievens NY, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced non small cell lung cancer. Eur Respir J 2006; 27: 895–901PubMed
3.
Woodward RM, Brown ML, Stewart ST, et al. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer Published Online: 2007; 11: 2511–8
4.
Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132 [Suppl.]: 1S-19SCrossRef
5.
Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898–907PubMedCrossRef
6.
Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22: 3524–30PubMedCrossRef
7.
Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004; 90: 397–402PubMedCrossRef
8.
Du W, Reeves JH, Gadgeel S, et al. Cost-effectiveness and lung cancer clinical trials. Cancer 2003; 98: 1491–6PubMedCrossRef
9.
Evans WK, Will BP, Berthelot JM, et al. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72: 1270–7PubMedCrossRef
10.
Hillner BE, Smith TJ. Overview of economic analysis of Le Chevalier vinorelbine study. Oncology 1998; 12: 14–7PubMed
11.
Koopmanschap MA, Van Roijen L, Bonneux L, et al. A detailed description of the future costs of cancer. Eur J Cancer 1994; 30A: 60–5CrossRef
12.
Molinier L, Combescure C, Chouaïd C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 2006; 24(7): 651–9PubMedCrossRef
13.
Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80: 215–8PubMedCrossRef
14.
Braud AC, Lévy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003; 21(9): 671–9PubMedCrossRef
15.
Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005; 50: 143–54PubMedCrossRef
16.
Fleming I, Monaghan P, Gavin A, et al. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 2008; 9 (1): 79–86PubMedCrossRef
17.
18.
Ng R, Hasan B, Mittmann N, et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer. J Clin Oncol 2007; 25: 2256–61PubMedCrossRef
19.
Barbera L, Walker H, Foroudi F, et al. Estimating the benefit and cost of radiotherapy for lung cancer. Int J Technol Assess Health Care 2004; 20: 545–51PubMedCrossRef
20.
Robinson LA, Ruckdeschel JC, Wagner H, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132: 243S-65CrossRef
21.
Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132: 266S-76CrossRef
22.
Evans WK, Will BP, Berthelot JM, et al. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997; 15: 3038–48PubMed
23.
Vergnenegre A, Combescure C, Fournel P, et al. GFPC (Groupe Français de Pneumo-Cancisérologie). Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01). Ann Oncol 2006; 17: 1269–74PubMedCrossRef
24.
Lievens Y, Kesteloot K, Bogaert W. CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol 2005; 75: 171–8PubMedCrossRef
25.
Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999; 52: 137–48PubMedCrossRef
26.
Kramer GW, Wanders SL, Noordijk EM, et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol 2005; 23: 2962–70PubMedCrossRef
27.
van den Hout WB, Kramer W, Noordijk ED, et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Nat Cancer Inst 2006; 24: 1786–94CrossRef
28.
Earle CC, Evans WK. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control 1997; 1: 282–8PubMed
29.
Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 10: 828–36CrossRef
30.
Maslove L, Gower N, Spiro S, et al. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Thorax 2005; 60: 564–9PubMedCrossRef
31.
Billingham LJ, Bathers S, Burton A, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37: 219–25PubMedCrossRef
32.
Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabin alone and combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20 (5): 325–37PubMedCrossRef
33.
Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8: 1301–9PubMed
34.
Kennedy W, Reinharz D, Tessier G, et al. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. Pharmacoeconomics 1995; 8 (4): 316–23PubMedCrossRef
35.
Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and costeffectiveness of paclitaxel, docetaxel, gemcitabin and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001; 5: 1–195
36.
Sacristan JA, Kennedy-Martin T, Rosell R, et al. Economic evaluation in a randomized phase III clinical trial comparing gemcitabin/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 2000; 28: 97–107PubMedCrossRef
37.
Neymark N, Lianes P, Smit EF, et al. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005; 23 (11): 1155–66PubMedCrossRef
38.
Pimentel FL, Bhalla S, Laranjeira L, et al. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 2006; 52: 365–71PubMedCrossRef
39.
Novello S, Kielhorn A, Stynes G, et al. Italian Lung Cancer Project Investigators. Cost-minimisation analysis comparing gemcitabin/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 2005; 48: 379–87PubMedCrossRef
40.
Rubio-Terrés C, Tisaire JL, Kobina S, et al. Cost-minimisation analysis of three regimens of chemotherapie (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small cell lung cancer. Lung Cancer 2002; 35: 81–9PubMedCrossRef
41.
Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291–7PubMedCrossRef
42.
Comella P, Frasci R, Panza N, et al. Randomized trial comparing cisplatin, gemcitabin, and vinorelbine with either cisplatin and gemcitabin or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. Clin Lung Cancer 2000; 1: 202–7PubMedCrossRef
43.
Schiller J, Tilden D, Aristides M, et al. Retrospective cost analysis of gemcitabin in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004; 43: 101–12PubMedCrossRef
44.
Tennvall GR, Fernberg JO. Economic evaluation of gemcitabin single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer. Med Oncol 1998; 15 (2): 129–36PubMedCrossRef
45.
Scagliotti GV, De Marinis F, Rinaldi M, et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285–91PubMedCrossRef
46.
Annemans L, Giaccone G, Vergnenegre A. The cost effectiveness of paclitaxel (taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999; 10: 605–15PubMedCrossRef
47.
Earle CC, Evan WK. Cost effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80: 815–20PubMedCrossRef
48.
Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomised clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13: 2166–73PubMed
49.
Maniadakis N, Fragoulakis V, Pallis A, et al. Economic evaluation of docetaxel/gemcitabin versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007; 58: 275–81PubMedCrossRef
50.
Horn L, Visbal A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging 2007; 24: 411–28PubMedCrossRef
51.
Le Lay K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007; 8: 145–51PubMedCrossRef
52.
Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 1344–52PubMedCrossRef
53.
Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004; 22 (9): 581–9PubMedCrossRef
54.
Bushill-Matthews L, Jackson D, Aristides M, et al. Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting. Eur J Cancer Suppl 2003; 1: 231CrossRef
55.
Pavlakis N, Mitchell PL, Stynes G. Cost-effectiveness of permetrexed for previously treated advanced non-small cell lung cancer. American Society of Clinical Oncology 2005 May 13–17; Orlando (FL)
56.
Chouaid C, Monnet I, Robinet G, et al. Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 2007; 23: 1509–15PubMedCrossRef
57.
Côté I, Leighl NB, Gyldmark M, et al. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the Canadian public health care perspective [abstract]. Value Health 2006; 6: A279CrossRef
58.
Lewis G, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non small cell lung cancer (SNCL) in UK [abstract]. Value Health 2006; 6: A203CrossRef
59.
Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatment for refractory non small cell lung cancers. Lung cancer 2008; 61: 405–15PubMedCrossRef
Metadaten
Titel
Economics of Treatments for Non-Small Cell Lung Cancer
verfasst von
Prof. Christos Chouaid
Kukovi Atsou
Gilles Hejblum
Alain Vergnenegre
Publikationsdatum
01.02.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 2/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200927020-00003

Weitere Artikel der Ausgabe 2/2009

PharmacoEconomics 2/2009 Zur Ausgabe

Review Article

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine

Original Research Article

Challenges in Merging Medicaid and Medicare Databases to Obtain Healthcare Costs for Dual-Eligible Beneficiaries

Editorial

Controlling Cervical Cancer

Original Research Article

Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV

Leading Article

Neuropathic Pain

Original Research Article

Willingness to Pay for a Treatment for Pain in Multiple Sclerosis